Boston Scientific Corp


SKU: BSX Category:


Like most medical device manufacturers, Boston Scientific Corporation also witnessed a slowdown in 2020 on account of the lower demand for medical devices and the deferral of elective surgeries. The company witnessed its fair share of Covid disruptions but appears to be on a recovery path lately delivering better than expected results for Q1 2021. This can be largely associated with new and ongoing product launches like Ranger DCB, Eluvia DES, POLARx catheter, LUX-Dx implantable cardiac monitor, and their Vercise Genus Deep Brain Stimulation platform. The company’s strength in the U.S. and the Asia Pacific regions has been a key driver behind the improving numbers. Moreover, the acquisition of Preventice and Lumenis is expected to bode well with the firm’s long-term growth trajectory.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $496 annual subscription!